Clinical Trials
8 trialsNCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04483778 2026-04-28
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown